uniQure's Lead HD Program AMT-130 Faces FDA Setback, ALS Program Discontinued Amid Q1 Loss; Strong Cash Runway Maintained

summarizeSummary

uniQure reported an increased Q1 net loss and a significant FDA setback for its lead Huntington's disease candidate, AMT-130, requiring a new trial. The company also discontinued its AMT-162 ALS program but affirmed a strong cash runway into the second half of 2029.

check_boxKey Events

• FDA Setback for Lead Candidate AMT-130

  The FDA determined that Phase I/II data for AMT-130 in Huntington's disease is insufficient to support a marketing application, requiring a new clinical trial. A Type B meeting is scheduled for Q2 2026 to discuss new trial design.

• Discontinuation of AMT-162 ALS Program

  Development of the AMT-162 program for SOD1 amyotrophic lateral sclerosis (ALS) has been discontinued following a dose-limiting toxicity observed in a patient during the Phase I/II EPISOD1 trial.

• Strong Cash Runway Maintained

  uniQure reported $586.6 million in cash, cash equivalents, and current investment securities as of March 31, 2026, providing a cash runway into the second half of 2029.

• Progress in UK Regulatory Path for AMT-130

  Following a successful pre-submission meeting with the UK MHRA, the company expects to submit a Marketing Authorization Application (MAA) for AMT-130 in the third quarter of 2026.

auto_awesomeAnalysis

This filing reveals significant clinical setbacks for uniQure's pipeline, particularly for its lead Huntington's disease candidate, AMT-130, which the FDA has deemed insufficient for a marketing application based on current Phase I/II data, necessitating a new trial. The outright discontinuation of the AMT-162 ALS program due to safety concerns further compounds the negative clinical news. While the company reported an increased net loss for Q1 2026, the affirmation of a strong cash runway into the second half of 2029 is a critical mitigating factor, providing the financial stability needed to navigate these challenges and fund future trials. Investors should monitor the outcome of the upcoming FDA Type B meeting for AMT-130 and the progress of the UK regulatory path, as well as the upcoming AMT-260 data.